{"type":"trials","record":{"id":42093,"source_id":"clinicaltrials-gov","external_id":"NCT04626128","title":"Safety and Tolerability Study of Suprachoroidal Injection of CLS-AX Following Anti-VEGF Therapy in Neovascular AMD","brief_summary":"To evaluate the safety and tolerability of suprachoroidally administered CLS-AX following intravitreal anti-VEGF therapy in subjects with neovascular age-related macular degeneration (AMD)","overall_status":"Completed","phases":["PHASE1","PHASE2"],"study_type":"INTERVENTIONAL","sponsor":"Clearside Biomedical, Inc.","enrollment":27,"countries":["United States"],"start_date":"2020-12-15","completion_date":"2022-10-13","last_update_date":"2023-09-18","source_url":"https://clinicaltrials.gov/study/NCT04626128","editorial_summary":"A registered PHASE1, PHASE2 study indexed because it matched monitored longevity research terms. Registry status: Completed. Registration does not establish safety or effectiveness.","first_seen_at":"2026-09-25T01:25:30.378222+00:00","last_seen_at":"2026-09-25T06:20:47.789+00:00","metadata":{"sex":"ALL","acronym":"OASIS","age_range":"50 Years","comparator":null,"organization":"Clearside Biomedical, Inc.","interventions":["CLS-AX","Anti-VEGF"],"registry_source":"ClinicalTrials.gov","outcome_measures":["Number of Participants With Treatment-emergent Adverse Events (TEAEs) — Day 1 to Week 12","Number of Participants With Serious Adverse Events — Day 1 to Week 12","Mean Change From Baseline in Pre Injection Intraocular Pressure (IOP) — Weeks 4, 8 and 12.","Number of Participants Receiving Additional Intravitreal (IVT) Aflibercept Injections — From Day 1 to Week 12","Number of Participants Qualifying to Receive Additional Intravitreal (IVT) Aflibercept Injections — Day 1 to Week 12","Mean Change From Baseline (Visit 2) in Central Subfield Thickness (CST) in the Study Eye — Weeks 4, 8 and 12","Mean Change From Baseline (Visit 2) in Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye — Weeks 4, 8 a…","Maximum Plasma Concentration [Cmax] of Axitinib — Day 1 to Week 12"],"design_description":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","source_has_results":true},"controlled_terms":["Neovascular Age-related Macular Degeneration","CLS-AX","Anti-VEGF"],"relevance_confidence":100,"source_quality_score":100,"freshness_score":50,"publication_state":"published","match_explanation":"Abstract contains controlled term: age-related macular degeneration.","quality_checked_at":"2026-09-25T06:20:59.355028+00:00","duplicate_cluster_key":"id:nct04626128","duplicate_of_id":null,"evidence_snapshot":{"status":"structured","version":1,"duration":"2020-12-15 to 2022-10-13","comparator":null,"confidence":"structured-source","population":"ALL · 50 Years","provenance":{"duration":"start_date and completion_date","comparator":"registry arm fields","population":"registry eligibility fields","intervention":"registry intervention fields","participants":"enrollment","study_design":"study_type and registry design fields","evidence_stage":"phases","reported_outcome":"not available","outcomes_measured":"registry outcome-measure fields"},"generated_at":"2026-09-25T06:20:47.919Z","intervention":["CLS-AX","Anti-VEGF"],"participants":27,"study_design":"NON RANDOMIZED · SEQUENTIAL · TREATMENT · NONE","subject_scope":"Human clinical study registration","evidence_stage":"PHASE1, PHASE2","safety_context":"Eligibility, adverse-event details, and clinical decisions must be checked in the official registry and with qualified clinicians.","source_support":"Structured registry protocol metadata; no finding-level conclusion is generated.","main_limitation":"This is a study registration. No reusable structured result is available here, so it cannot show whether the intervention worked or was safe.","reported_outcome":null,"outcomes_measured":["Number of Participants With Treatment-emergent Adverse Events (TEAEs) — Day 1 to Week 12","Number of Participants With Serious Adverse Events — Day 1 to Week 12","Mean Change From Baseline in Pre Injection Intraocular Pressure (IOP) — Weeks 4, 8 and 12.","Number of Participants Receiving Additional Intravitreal (IVT) Aflibercept Injections — From Day 1 to Week 12","Number of Participants Qualifying to Receive Additional Intravitreal (IVT) Aflibercept Injections — Day 1 to Week 12","Mean Change From Baseline (Visit 2) in Central Subfield Thickness (CST) in the Study Eye — Weeks 4, 8 and 12","Mean Change From Baseline (Visit 2) in Best Corrected Visual Acuity (BCVA) Letter Score in the Study Eye — Weeks 4, 8 a…","Maximum Plasma Concentration [Cmax] of Axitinib — Day 1 to Week 12"],"regulatory_context":"Trial registration is not regulatory approval and does not establish that an intervention is available."},"clinical_trial_topics":[{"topic_slug":"vision-aging","is_published":true,"match_reasons":["Abstract contains controlled term: age-related macular degeneration.","Source terminology contains: age-related macular degeneration.","Abstract supplies longevity context: age-related.","Study type is explicitly identified as INTERVENTIONAL."],"matched_fields":["abstract","controlled terminology","abstract context","study type"],"relevance_score":100,"intelligence_topics":{"name":"Vision ageing","slug":"vision-aging"}}],"content_sources":{"name":"ClinicalTrials.gov","homepage_url":"https://clinicaltrials.gov/"}},"canonical_url":"https://www.immortal.life/trials/42093","automation_disclosure":"Generated automatically from cited source metadata. No scientist, clinician, researcher, editor, or human reviewer evaluates this publication before release."}